Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Completed Initiated May 27, 2025 (17 months ago)

Fluoxetine Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

Fluoxetine Tablets, USP, 20 mg, 28-count Carton (4x7 Unit-dose), Manufactured by: TORRENT PHARMACEUTIALS LTD., Indrad-382 721 INDIA; Manufactured for: TORRENT PHARMA INC., Basking Ridge, NJ 07920. NDC: 13668-473-91 (Carton); 13668-473-70 (Blister)

Affected NDCs 13668-0473-70 13668-0473-91

Compare with the code on your package — it is the most precise check available.

Drug: Fluoxetine Category: Mental Health Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Fluoxetine
NDC 13668-0473
HYDROCHLORIDE 20 mg/1 Tablet
Oral
Torrent Pharmaceuticals Limited Rx
Recalling firm
Torrent Pharma Inc.
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0456-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Fluoxetine recalls

See all
Class II · Moderate risk

Fluoxetine Tablets

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Completed Nitrosamine impurity Torrent Pharma Inc. D-0455-2025
Class III · Low risk

Fluoxetine Tablets USP

Failed impurities/ degradation specifications: Teva Pharmaceuticals USA, Inc. is voluntarily recalling all lots within expiry due to out of specification (OOS) test result for the lactoside impurity obtained during routine stability testing activities.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 0093-7188-56 D-0578-2018
Class II · Moderate risk

Fluoxetine Capsules USP

Chemical Contamination: Product recalled due to an elevated level of a residual solvent impurity in the API that exceeds the Threshold of Toxicological Concern (TTC) calculation for the impurity.

Terminated Chemical / undeclared Teva Pharmaceuticals USA NDC 50111-648-02 D-0971-2015
Class II · Moderate risk

Fluoxetine Capsules USP

Chemical Contamination: Product recalled due to an elevated level of a residual solvent impurity in the API that exceeds the Threshold of Toxicological Concern (TTC) calculation for the impurity.

Terminated Chemical / undeclared Teva Pharmaceuticals USA NDC 50111-647-01 D-0970-2015
Class III · Low risk

Fluoxetine Capsules USP

Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.

Terminated Labeling / mix-up Sandoz Incorporated NDC 0781-2822-01 D-0291-2015

Other recalls by Torrent Pharma Inc.

All 2025 recalls
Class II · Moderate risk

Fluoxetine Tablets

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Completed Nitrosamine impurity Torrent Pharma Inc. D-0455-2025